Development of a new treatment method using glycolipids for anticancer drug-resistant cancer in gynecologic cancers
| Project/Area Number |
17K11295
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Toho University (2018-2021)
Keio University (2017) |
|---|
Principal Investigator |
TANAKA KYOKO 東邦大学, 医学部, 教授 (10286536)
|
|---|
| Project Period (FY) |
2017-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 子宮内膜癌 / 子宮頸癌 / 卵巣癌 / 糖脂質 / 抗癌剤耐性 / 遺伝子導入 / 子宮頸癌由来細胞株 / ガングリオシド / ヌードマウス / 皮下移植 / 抗癌剤感受性 / 婦人科癌 / 抗がん剤耐性 / 糖鎖 |
|---|
| Outline of Final Research Achievements |
We investigated glycolipid composition in gynecological cancer tissues (endometrial cancer, cervical cancer, and ovarian cancer) and found that each cancer has a characteristic composition. In endometrial cancer, sulfatide synthase genes were introduced into endometrial cancer-derived cells, and sulfatide was found to be an indicator of anticancer sensitivity and drug resistance. In cervical cancer, GM2 was found to be a key factor for cancer growth by comparing cell lines and cancer tissues.
|
| Academic Significance and Societal Importance of the Research Achievements |
細胞の癌化に伴う複合糖鎖の変化はすべての癌細胞に観察され、消化管、内分泌器官などの癌細胞では特定の糖鎖が腫瘍マーカーとして癌の臨床診断に用いられている。本研究では子宮内膜癌、子宮頸癌、卵巣癌における糖脂質の組成を解析し、癌細胞の転移、抗がん剤耐性への糖鎖の関与を明らかにしたことで癌の治療効果を高めるための基礎研究を行うことができた。
|
Report
(6 results)
Research Products
(7 results)
